AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Galectin Therapeutics Inc.
Video analysis: GALT
All videosNo video analysis for this stock yet. Request one from our team.
News: GALT
Galectin Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
NORCROSS, Ga., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that company management will present and attend the H.C.
Reviewing Galectin Therapeutics (NASDAQ:GALT) & SQZ Biotechnologies (NYSE:SQZ)
SQZ Biotechnologies (NYSE: SQZ - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk. Profitability This table compares SQZ Biotechnologies and
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200-Day Moving Average – Here’s What Happened
Galectin Therapeutics Inc. (NASDAQ: GALT - Get Free Report) shares passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $3.04 and traded as high as $4.21. Galectin Therapeutics shares last traded at $4.15, with a volume of 291,096 shares. Wall Street Analysts Forecast Growth A number
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
NORCROSS, Ga., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended June 30, 2026.
Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet
Chairman Richard E. Uihlein converts outstanding notes under five line of credit facilities into common stock Transaction eliminates approximately $105.8 million in debt and increases market capitalization NORCROSS, Ga.
Galectin De-Risks Belapectin Path With FDA Alignment - Sets Stage For Phase 3 Upside
Galectin Therapeutics remains a buy as recent FDA alignment de-risks belapectin's Phase 3 path and clarifies regulatory endpoints. The FDA's endorsement of a single, well-controlled Phase 3 trial with a composite clinical outcome endpoint reduces uncertainty and shortens timelines. GALT's valuation reflects skepticism about execution, financing risk, and commercial viability, but successful Phase 3 results could trigger a significant re-rating.
GALT Jumps 11% on FDA Alignment for Belapectin Phase III Path in MASH
Galectin stock rises following FDA alignment on key elements of belapectin's phase III MASH cirrhosis program, clarifying a potential path toward full approval.
